Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen effective Tax Rate Reconciliation — Interest on Unrecognized Tax Benefits (legacy) (%) (%)
Form 10-K Income Taxes Note (XBRL)
Latest, FY2024
4.2%
Period ended Dec 31, 2024
Change on a year earlier
+1.6 pts
2.6% in FY2023
History
9 years
Since FY2016
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Effective Tax Rate Reconciliation — Interest on Unrecognized Tax Benefits (legacy) (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 4.2% | +1.6 pts | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 2.6% | +0.7 pts | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 1.9% | +0.8 pts | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 1.1% | 0.0 pts | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 1.1% | -0.5 pts | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 1.6% | +0.4 pts | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 1.2% | +0.6 pts | Form 10-K (filed 2021-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 0.6% | +0.1 pts | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 0.5% | – | Form 10-K (filed 2019-02-13) ↗ |
Cite this data
StockData. (2026). Amgen Effective Tax Rate Reconciliation — Interest on Unrecognized Tax Benefits (legacy) (%) (%), annual FY2016–FY2024 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/etr_utb_int
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.